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Abstract 
Various non-viral delivery systems for small interfering RNAs (siRNA) have been 
developed. Such delivery systems generally exhibit tightly formed spherical structures. While 
such carriers have demonstrated good transfection activity in mono-layered cell systems, effects 
against solid tumors are often less apparent and difficult to demonstrate, likely due to the rigid 
structures of the carriers, which may prevent penetration to deeper regions within tumor tissue. 
Herein, we developed a flexible nanocarrier (FNC) system that is able to penetrate to deeper 
regions within tumor tissue. Specifically, we employed previously found flexible polyplexes 
comprised of siRNA and poly-L-lysine as wick structures for the preparation of FNCs. FNCs 
were constructed by coating the wick structures with lipids using a liposomal membrane fusion 
method. The diameters of the resulting FNCs were ca. 170 nm, and the shapes were 
non-spherical. Lipid coating was confirmed using a nuclease resistance assay. Furthermore, 
FNCs showed significant RNA interference effects, comparable to Lipofectamine 2000, in a 
mono-layered cell system. To accelerate tumor penetration, the FNC surface was modified with 
polyethylene glycol (PEG) and the tight junction opener peptide AT1002. Surface-modified 
FNCs demonstrated effective penetrability into a cancer spheroid. Thus, we developed a novel 
and unique tumor-penetrable siRNA FNC system. 
Keywords: flexible nanocarrier; intercellular penetrability; siRNA/PLL polyplexes  
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Introduction 
Small interfering RNA (siRNA) is expected to become a novel and effective nucleic 
acid medicine for cancer therapy (Boccellino, 2015; Kim, 2016). Effective anti-cancer 
therapeutic applications, however, require delivery of siRNA to the tumor site. Various non-viral 
delivery systems, such as polyplexes and lipoplexes, have been developed to deliver siRNA to 
tumor sites (Ballarín-González, 2014; Ozpolat, 2014; Zhang, 2014; Kim, 2016). In general, such 
delivery systems are typically spherical nanoparticles comprised of tightly condensed core 
structures that are formed via electrostatic interactions (Akita, 2010; Ballarín-González, 2014). 
Effective anti-cancer therapeutic carriers need to be able to penetrate into deep regions of tumor 
tissue through the narrow gaps that exist between cancer cells. Moreover, the rigid structures of 
such carriers are disadvantageous for deep penetration into tumor tissue through the intercellular 
space. In fact, penetration capability of nanoparticles depends on size. Kataoka’s group found 
that 30 nm nanoparticles efficiently penetrated into tumor tissue, although penetration of 70 nm 
nanoparticles was not effective (Nishiyama 2016). Thus, smaller size would be suitable for 
penetration through the narrow gaps among cancer cells. In addition, nanoparticles modified 
with functional devices, such as cyclic tumor homing peptide, showed high permeability into 
tumor (Song 2016). Furthermore, it has been reported that ultra-formable liposomes, which have 
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high flexibility, have high permeability into skin tissues (Subongkot 2014). Therefore, it was 
suggested that the more flexible carrier structures would be required for penetration into tumor.  
Previously, we found that polyplexes comprised of siRNA and poly-L-lysine (PLL) 
were able to pass through acrylamide gel, while other polyplexes of siRNA condensed with 
stearyl-octaarginine or protamine were unable to migrate in the gel (Nakamura, 2007). These 
results suggest that siRNA/PLL polyplexes form flexible structures that allow for penetration 
through narrow spaces in acrylamide gel, and that such structures may also be expected to 
penetrate through narrow intercellular gaps. As siRNA is known to be sensitive to nuclease 
activity, lipid coating of the flexible polyplexes is required for protection against nuclease attack, 
so we attempted to design a novel siRNA carrier comprised of a lipid-coated flexible 
siRNA/PLL polyplex.  
Specifically, in the present study, we prepared wick structures comprised of siRNA 
and PLL, and constructed flexible nanocarriers (FNCs) by coating the wick structures with lipid 
membranes as shown in Figure 1. A previously developed liposomal membrane fusion method 
was employed to coat the polyplexes with a lipid bilayer to prepare a multifunctional envelope 
nano-device (MEND) (Nakamura, 2006; Akita, 2010). The functionality of the resulting FNCs 
was evaluated, including RNA interference (RNAi) effects and penetrability. Furthermore, based 
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on the results of the penetration study, the FNC surface was modified with functional devices to 
allow for accelerated penetrability.   
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Materials and Methods 
Materials 
Poly-L-lysine (PLL) (MW 23,900) was purchased from Sigma-Aldrich, Inc. (St. Louis, 
MO, USA). Alexa 546-labeled siRNA (21-mer, 
5’-Alexa546-UAUUGCGUCUGUACACUCUCATT-3’, 
5’-Alexa546-UGAGUGUACAGACGCAAUATT-3’) and anti-luciferase siRNA (21-mer, 
5’-GCGCUGCUGGUGCCAACCCTT-3’, 5’-GGGUUGGCACCAGCAGCGCTT-3’) were 
obtained from Invitrogen Life Technologies (Carlsbad, CA, USA). 
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and 
7-nitrobanz-2-oxa-1,3-diazole-DOPE (NBD-DOPE) were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). N-(carbonyl-methoxypolyethyleneglycol 
2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (PEG2000-DSPE) was purchased from 
the NOF Corporation (Tokyo, Japan). Lipofectamine 2000 (LFN) was obtained from Invitrogen 
Life Technologies (Carlsbad, CA, USA). Stearylated AT1002 
(Stearyl-Phe-Cys-Ile-Gly-Arg-Leu-NH2) was synthesized by Scrum Inc. (Tokyo, Japan). The 
mouse melanoma cell line B16-F1 was obtained from Dainippon Sumitomo Pharma Biomedical 
Co, Ltd. (Osaka, Japan), and stable transformants of B16-F1 cells expressing luciferase 
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(B16-F1-Luc) were established in our laboratory (Hama, 2012a). These cells were cultivated in 
DMEM supplemented with 10% FBS at 37°C in 5% CO2. 
 
Construction of flexible nanocarriers (FNCs) 
A schematic of the FNC construction process is shown in Figure 1. The FNC 
construction process consists of two steps: (1) siRNA solution is mixed with poly-L-lysine 
solution to form a negatively charged wick structure via electrostatic interactions, and (2) 
cationic liposomes comprised of DOTAP/DOPE (1:1) are added to the wick structure 
suspension. The cationic liposomes associate with the surfaces of the negatively charged wick 
structures, and the wick structures are then coated with lipid membranes via membrane fusion 
between liposomes containing the membrane-fusible lipid DOPE, resulting in the formation of 
FNCs.  
Wick structures were prepared by gently mixing a drop of siRNA solution (0.05 
mg/ml) with a drop of PLL solution (0.1 mg/ml), and allowing the mixture to incubate for 10 
min at room temperature. The cationic liposomes were prepared using a lipid hydration method 
(Hama 2012b, 2012c). Chloroform solution containing 0.1 μmol DOTAP and 0.1 μmol DOPE 
was dried to a thin film under vacuum in a test tube. The dried lipid film was hydrated with 0.4 
mL 10 mM Tris buffer (pH 7.4) at room temperature to obtain a liposomal suspension, and 
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liposomes were produced by sonication in a bath-type sonicator (AU-25C, Aiwa, Tokyo, Japan). 
To modify the FNC surface, a solution of stearylated AT1002 and/or PEG-DSPE was added to 
the FNC suspension, and the mixture was incubated for 30 min at room temperature. Amounts 
of stearylated AT1002 and PEG-DSPE were 5 mol% and 1 mol% of total lipids, respectively. 
The diameters and zeta-potentials of the resulting wick structures, liposomes and FNCs were 
measured by dynamic light scattering and laser Doppler using a Zetasizer nano (Malvern 
Instruments Ltd, UK). 
 
Native polyacrylamide gel electrophoresis of siRNA 
Solutions of siRNA (20 pmol) mixed with PLL solution at various nitrogen/phosphate 
(N/P) ratios were subjected to native polyacrylamide gel electrophoresis using 15% 
polyacrylamide gel at 10.5 mA for 30 min. Following electrophoresis, the gel was stained with 
SYBR Gold solution (Invitrogen Life Technologies, Carlsbad, CA, USA) for 30 min, and the 
gel was observed under a UV transilluminator. 
 
Ethidium bromide (EtBr) exclusion assay of wick structures prepared at various N/P ratios 
A solution containing 0.1 g EtBr was added to the suspension of wick structures 
containing 0.25 g siRNA for intercalation of EtBr into siRNA. The fluorescence intensity of 
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EtBr intercalated in siRNA was then measured at an excitation wavelength of 260 nm and an 
emission wavelength of 630 nm (Sutton, 2006).  
 
Sucrose density gradient fractionation analysis of FNCs 
Labeling of both the siRNA and FNC lipid membrane was carried out by mixing a 
siRNA solution containing 10% Alexa546-labeled siRNA and a lipid mixture containing 1% 
NBD-DOPE. The labeled FNC sample was then applied to a discontinuous sucrose density 
gradient (0 - 60%), and ultracentrifugation was performed at 220,000 × g for 2 h at 20°C. After 
ultracentrifugation, 1 mL of solution was collected at a time. Fluorescence intensities of both 
Alexa and NBD in each fraction were measured at an excitation 546 nm/emission 573 nm and 
excitation 459 nm/emission 534 nm, respectively.  
 
RNase protection assay 
An RNase protection assay was performed according to our previous report (Yamada, 
2016). Briefly, the FNC sample was incubated in the presence of RNase (10 g/ml) for 2 h at 
37°C. The sample was then solubilized with detergent on ice, and subjected to electrophoresis 
using 2% agarose gel at 100 V for 20 min. After electrophoresis, the gel was stained with SYBR 
Gold solution for 30 min, and observed under a UV transilluminator. 
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Negative staining and transmission electron microscopic observation of FNCs 
The samples were absorbed to formvar film coated copper grids (400 mesh) and 
stained with 2% phosphor tungstic acid solution (pH 7.0) for 1 min. The samples were then 
observed using a transmission electron microscope (TEM) (JEM-1400Plus; JEOL Ltd., Tokyo, 
Japan) at an acceleration voltage of 80 kV. Digital images (2048 × 2048 pixels) were taken with 
a CCD camera (VELETA; Olympus Soft Imaging Solutions GmbH, Münster, Germany). 
 
Transfection of FNCs containing anti-luciferase siRNA to cultured cells stably expressing 
luciferase 
B16-F1 cells stably expressing luciferase were seeded on a culture well (4 × 104 
cells/well). After 24 h, samples containing 15 pmol siRNA (60 nM) were added to the cultured 
cells and incubated for 48 h at 37°C. The cells were then solubilized with reporter lysis buffer. 
Luciferase activity of the cell lysate was measured as chemiluminescence intensity using a 
luminometer in the presence of luciferase assay reagent (Promega, Madison, WI, USA). The 
chemiluminescence intensity was compensated by protein amount evaluated with the BCA 
Protein Assay Kit (Thermo Fisher Scientific Inc., Waltham, MA, USA).   
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Penetrability of FNC into a cancer cell spheroid 
To prepare the spheroid, a suspension of B16-F1 cells (3 × 104 cells) was added to a 
well of a NanoCulture Plate (Scivax, Kawasaki, Japan). After 1 day, a lump of cells was 
transferred to a glass-bottom dish coated with PLL, and incubated for 3 days. FNCs comprised 
of Alexa 546-labeled siRNA and NBD-labeled lipid membranes were prepared for observation 
with a confocal laser scanning microscope. The FNC suspension containing 100 nM siRNA was 
added to the cell spheroid, and incubated for 24 h. After incubation, 10 L of 2.5 mM 
Hechest33342 was added, and the spheroid was incubated for 10 min at room temperature. The 
spheroid was then washed with DMEM without serum, and observed with a confocal laser 
scanning microscope (Nikon A1R, Nikon Tokyo). 
 
Statistical analysis 
Statistical analysis was performed using one-way ANOVA followed by Turkey-Kramer honest 
significant difference (HSD) test. P values <0.05 were considered to be significant; they were 
evaluated using JMP software (SAS Institute Inc. Cary, North Carolina, USA). 
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Results and Discussion 
Preparation of wick structures comprised of siRNA and PLL 
In our previous study, complexes of siRNA with PLL were prepared at an N/P ratio of 
2.4, and were shown to penetrate through an acrylamide gel (Nakamura, 2007). In this study, we 
prepared siRNA/PLL complexes at various N/P ratios in an effort to find optimum condition for 
preparation of flexible wick structures of FNC. Complexes prepared at an N/P ratio 0.2 resulted 
in the appearance of novel bands at around 200 bp, while only one band attributed to siRNA 
was observed for complexes prepared at an N/P ratio of 0.1 (Figure 2). The intensities of the 
higher bands around 200 bp were found to increase with increasing N/P ratios. In contrast, no 
bands were observed at 200 bp for complexes prepared using an N/P ratio of 3.2 (Figure 2), 
indicating that the complexes prepared at this N/P ratio could not penetrate into the acrylamide 
gel. In Figure 2, two apparent bands around 200 bp were recognized. Thus, two fractions of 
wick structure would be formed by mixing of siRNA with PLL. Different numbers of siRNA 
would bind with PLL, although it is difficult to estimate the exact number of siRNA binding 
with PLL. The size and surface charges of a series of wick complexes prepared at N/P from 0.1 
to 3.2 were measured (Supplemental table 1). Diameters of all complexes were over 150 nm. At 
N/P ratio 3.2, zeta-potential of the complex was positive, although the complexes prepared at 
lower N/P ratios showed negative zeta-potential. The size and surface charge of complexes were 
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not same. However, migrations of wick complexes prepared at all N/P ratios in gel 
electrophoresis were almost the same. Thus, the migration of complexes would not be affected 
by the size and surface charge in this study. 
To precisely evaluate the formation of complexes comprised of siRNA and PLL, an 
EtBr exclusion assay was performed. Since EtBr can intercalate into double stranded nucleic 
acids (Sutton, 2006), the fluorescence intensity of EtBr can be used as an indicator of the 
formation of typical complexes, which would have tight structure. As shown in Figure 3, EtBr 
fluorescence exhibited similar intensities for complexes prepared at N/P ratios <1.0, while EtBr 
fluorescence decreased for complexes prepared at N/P ratios >1.0. These results suggest that 
typical complexes are prepared using N/P ratios >1.0. Thus, a fixed N/P ratio of 0.8 was used 
for the preparation of siRNA/PLL complexes to serve as wick structures to subsequently prepare 
FNCs. Diameters and zeta-potentials of the resulting wick structures were ca. 293 nm and -13 
mV, respectively (Table 1). 
 
Construction of FNCs by the liposomal membrane fusion method 
To protect siRNA from nuclease activity, wick structures were coated with lipid 
membranes. We previously developed a lipid coating method via membrane fusion of liposomes 
to construct a spherical gene delivery system coated with two lipid membranes (Nakamura, 
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2006; Akita 2010). As liposomal membrane fusion was also expected to be suitable for coating 
the wick structures, we applied the same liposomal membrane fusion method to prepare the 
FNCs in this study.  
When positively charged liposomes containing the membrane-fusible lipid DOPE 
(with diameters and zeta-potentials ca. 130 nm and 27 mV, respectively [Table 1]) were added to 
the wick structure suspension, the liposomes easily fused with each other upon binding to the 
negatively charged surfaces of the wick structures via electrostatic interactions. After mixing the 
wick structure suspension with liposomes, the diameters and zeta-potentials of the resulting 
sample were ca. 170 nm and 23 mV, respectively (Table 1). The negative surface charge of the 
wick structures was inverted to positive upon mixing with liposomes. The sample was then 
subjected to density gradient ultracentrifugation fractionation analysis (Fig. 4). Significant 
amounts of lipid were detected in fractions #1 and #2, indicating that empty liposomes exist in 
those low-density fractions. On the other hand, only siRNA was recognized in fractions #11 and 
#12, suggesting that these fractions only contained wick structures. Fractions #4 - #6 were 
found to contain siRNA co-localized with lipid, suggesting that the lipid-coated wick structures, 
i.e., FNCs, were contained in those fractions. The percentage of siRNA encapsulated into FNC 
was calculated from the result of density gradient ultracentrifugation fractionation analysis 
(Figure 4). The encapsulation percentage of siRNA in FNC was 51 %. 
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An RNase protection assay was carried out to confirm lipid coating of the wick 
structures (Fig. 5). In the absence of RNase, two bands were observed in the wick structure 
sample, namely a lower band corresponding to free siRNA, and an upper band corresponding to 
the wick structures (Fig. 5). When both free siRNA and the wick structures were treated with 
RNase, bands corresponding to siRNA disappeared, suggesting that the RNasse degraded the 
siRNA (Fig. 5). In the case of FNCs, an upper band was recognized even in the presence of 
RNase, while the lower band was found to disappear in the presence of RNase (Fig. 5). Taken 
together, these results suggest that only free siRNA, without a lipid coating, was degraded by 
RNase, and that FNCs were successfully constructed via lipid coating of the wick structures. 
TEM was employed to examine the morphological structures of the resulting FNCs 
(Fig. 6). The shapes of the FNCs were found to be non-spherical, as evidenced by the elliptic 
particle shown in Fig. 6. Moreover, both lipid envelope structures and cavity spaces were 
recognized in the FNCs. In other images, similar non-spherical structures were also observed. In 
broader scope images of Supplemental figure 1, only one FNC was observed in the broader 
images because of low number of the nanoparticles in the diluted sample suspensions for TEM 
observation. In the broader images, small particles, which would be liposomes, were also 
observed. Based on the TEM images, the resulting shapes of the FNCs were different from those 
of more conventional delivery systems, such as lipoplexes and polyplexes. To clarify the reason 
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for non-spherical structure of FNC, the siRNA/PLL complexes were observed by AFM. As 
shown in the Supplemental figure 2, shape of siRNA/PLL complex was not a sphere, like a rod. 
Thus, the non-spherical structure of FNC would depend on the wick structure (siRNA/PLL 
complex). 
Regarding flexibility of FNC, we additionally performed the observation of FNC by 
atomic force microscope (AFM). As shown in AFM image (Supplemental figure 3), height of 
FNC was less 50 nm, although diameter was over 300 nm. On the other hand, diameter 
measured by DLS was approximately 170 nm (Table 1). From these results, it was suggested 
that the nanoparticles were flattened in the AFM image. Thus, FNC should be flexible structure, 
although siRNA/PLL complexes were encapsulated in the nanoparticles. 
 
Inhibitory effects of anti-luciferase siRNA-containing FNCs on luciferase activity of cultured 
cells 
To confirm the functionality of FNCs for potential use as siRNA carriers, transfection 
of anti-luciferase siRNA-containing FNCs was examined in cells stably expressing luciferase 
cultured on a plane surface, and compared with siRNA lipoplexes comprised of the 
conventional transfection reagent Lipofectamine 2000 (LFN/siRNA) (Fig. 7). The 
anti-luciferase activity of FNC encapsulating anti-luciferase siRNA was examined against plane 
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culture cells stably expressing luciferase, not spheroid. We previously examined the effect of 
FNCs encapsulating anti-luciferase siRNA on spheroid expressing luciferase. However, since 
FNCs were taken up by the cells not only inside but also outside of spheroid, it was difficult to 
evaluate RNAi effect by penetration of FNCs into inside of spheroid. Thus, we used plane 
culture cells for evaluation of gene knockdown capability of FNCs. As shown, both LFN/siRNA 
lipoplexes and FNCs significantly reduced luciferase activity in the mono-layered cells, 
suggesting that the RNAi effect of the latter was comparable to that of LFN/siRNA lipoplexes. 
As shown in the Supplemental figure 4, FNCs encapsulating anti-GFP siRNA showed no 
inhibition of luciferase activity. This result indicates that non-specific knockdown effect on 
luciferase activity was not recognized in this study. Thus, it was confirmed that reductions of 
luciferase activity in Figures 7 and 9 were specific RNAi effect of FNCs encapsulating 
anti-luciferase siRNA. Thus, FNC exhibits sufficient functionality as a siRNA carrier. 
 
Penetrability of FNCs into cancer cell spheroid through intercellular space 
To evaluate penetrability into a cancer cell spheroid, FNCs comprised of 
Alexa546-labeled siRNA (red)/PLL wick structures and NBD-labeled lipid membranes were 
prepared. FNCs labeled with fluorescent dyes were then incubated with the cancer spheroid, and 
the penetrability of FNCs into the spheroid was evaluated using a confocal laser scanning 
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microscope (Fig. 8). Minimal red fluorescence (siRNA) was recognized in a lump of cells; 
however, FNC penetration into the spheroid was not sufficient. To improve the penetrability, the 
FNC surface was modified with functional moieties. Based on previous reports, we selected 
AT1002 as a functional peptide moiety to allow for penetration through the intercellular space. 
AT1002 is a synthetic peptide comprised of six amino acids 
(Phe-Cys-Ile-Gly-Arg-Leu-Cys-Gly) known to induce reversible opening of tight junctions by 
changing the zonula occludens protein 1 (ZO-1), like Zonula occuluta toxin (Zot) (Song, 2008a, 
2008b). Previously, the Okada group reported that transdermal penetration of siRNA complexes 
was enhanced by co-application with AT1002 (Uchida, 2011a, 2011b). In this study, the FNC 
surface was modified by incubation with AT1002 conjugated with stearic acid. Modification 
with AT1002 (5 mol % of total lipids) did not change significantly the diameters or 
zeta-potentials of the FNCs (Table 1). However, the zeta-potential of FNCs was slightly 
decreased by modification with AT1002 or PEG, although the decrease in the zeta-potential was 
not statistically significant. Based on this result, it was suggested that AT1002 or PEG was 
loaded on the surface of FNCs.  
When AT1002-modified FNCs (AT1002-FNCs) were incubated with the spheroid, a 
potent red fluorescence signal was observed in the peripheral region of the spheroid, indicating 
aggregation of AT1002-FNC on the spheroid surface (Fig. 8). It is likely that the hydrophobic 
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amino acid residues (Phe, Ile and Leu) of the AT1002 peptide are responsible for the observed 
FNC aggregation. To prevent aggregation on the peripheral regions of the spheroid, the FNC 
surface was modified with polyethylene-glycol (PEG). No significant changes in zeta-potentials 
were observed upon modification with PEG (1 mol% of total lipids), while the diameters of the 
PEG-modified FNCs (PEG-FNCs) were slightly smaller than those of non-modified FNCs 
(Table 1). The PEG-FNCs were then incubated with the spheroid. Since red fluorescence of the 
PEG-FNCs was observed mainly on the surface of spheroid, it was suggested that the 
PEG-FNCs could not penetrate into the spheroid, despite the fact that aggregation should have 
been somewhat prevented by modification with PEG.  
FNCs equipped with both functional devices, namely AT1002 for intercellular 
penetration, and PEG for prevention of aggregation, were subsequently prepared. 
Physicochemical properties of the FNCs modified with both AT1002 and PEG 
(AT1002/PEG-FNCs) were nearly identical to those of PEG-FNCs (Table 1). Incubation of the 
AT1002/PEG-FNCs with the spheroid resulted in homogenously distributed red fluorescence 
throughout the spheroid, although some small amounts of aggregation were also observed (Fig. 
8). Based on these findings, it is suggested that the AT1002/PEG-FNCs exhibit the ability to 
penetrate into the narrow intercellular spaces of the spheroid. Thus, AT1002 and PEG represent 
a suitable combination for effective penetration into cellular clumps. Regarding spheroid 
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experiment, it would be ideal that spheroid structures are almost the same for better evaluation. 
In this study, we used mouse melanoma B16-F1 cells as cancer cells, and prepared spheroid of 
this melanoma cells, because we established B16-F1 cells stably expressing luciferase. However, 
the spheroid of B16-F1 cells was fragile. Thus, when the spherical spheroid was transferred 
from NanoCulture Plate to a glass-bottom dish, the shape was changed. In this study, FNC was 
not purified after mixing the wick complexes with liposomes. In our previous study, we 
developed novel liposomal-type gene delivery system octa-arginine modified multifunctional 
envelope-type nano device (R8-MEND) (Kogure 2007), and examined the effect of purification 
of R8-MEND encapsulating luciferase plasmid DNA on transfection activity. The luciferase 
activity of purified R8-MEND was lower than that of un-purified R8-MEND (Unpublished 
data). It was suggested that the empty R8-modified liposomes, which co-existed with 
R8-MEND in the suspension, were necessary for high functionality of the gene delivery 
nanoparticles. Thus, in this study, we did not purify FNCs. Probably, AT1002/PEG-modified 
liposomes, which co-existed with AT-1002/PEG-FNCs in the suspension, also contribute for 
opening intercellular junction. 
Since the FNCs were constructed as siRNA carriers, the knockdown activity of FNCs 
against specific gene expression should be maintained even after surface modification with 
AT1002 and PEG. To confirm this, transfections of FNCs containing anti-luciferase siRNA 
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modified with AT1002 and/or PEG were examined against B16-F1 cells stably expressing 
luciferase. The suppression activities of FNCs modified with AT1002, PEG and AT1002/PEG 
were nearly the same, and no statistical significant differences between non-modified and 
modified FNCs were observed, although the activity of non-modified FNCs was slightly 
decreased by modification (Fig. 9). These results indicate that surface modification with AT1002 
and/or PEG did not prevent the ability of FNCs to function as siRNA carriers.  
Regarding the surface modifications, PEG should also be useful for blood circulation 
to deliver FNCs to tumor tissue by the enhanced permeability and retention (EPR) effect. 
However, the PEG-to-AT1002 ratio should be optimized for such in vivo applications. It is 
currently difficult to optimize the PEG-to-AT1002 ratio for both protracted blood circulation 
and intercellular penetration using an in vivo tumor bearing animal model. In the future, 
however, such optimizations will be required for in vivo applications of AT1002/PEG-FNCs for 
cancer therapy. 
 
Conclusion 
In this study, flexible nanocarriers (FNCs) were developed that exhibit the ability to 
penetrate tumor tissue through the intercellular space. For effective intercellular penetration, the 
FNC surface was modified with the tight junction opener peptide AT1002. FNCs were further 
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modified with PEG for prevention of AT1002-mediated aggregation of FNCs on the surface of 
the cancer spheroid. The surface-modified FNCs were found to effectively penetrate into the 
cancer spheroid without any reduction in their ability to serve as siRNA carriers. In conclusion, 
a novel intercellular penetrable siRNA carrier was successfully developed based on a unique 
concept.  
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Table 1. Characteristics of the various structures prepared in this study 
Sample Diameter (nm) Poly dispersion index Zeta-potential (mV) 
Wick structures 293.1±76.7 0.35±0.12 -13.3±3.1 
Liposomes 127.4 ± 28.9 0.34 ± 0.07 26.5 ± 5.1 
FNCs 168.1 ± 27.9 0.26 ± 0.06 22.9 ± 6.6 
AT1002-FNCs 169.1 ± 25.9 0.28 ± 0.08 20.7 ± 5.3 
PEG-FNCs 154.5 ± 33.0 0.23 ± 0.08 20.4 ± 8.9 
AT1002/PEG-FNCs 151.8 ± 26.2 0.24 ± 0.06 20.8 ± 6.2 
Values are means ± SD obtained by measurement of at least three different samples. 
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Figure legends 
Figure 1.  
Schematic of the process for construction of flexible nanocarriers (FNCs) 
FNCs were constructed in two steps: (1) preparation of wick structures by mixing 
siRNA and poly-L-lysine, as poly-L-lysine and siRNA easily make a flexible complex via 
electrostatic interactions, and (2) lipid coating of wick structures. After addition of cationic 
liposomes to the wick structures, the liposomes associate on the surfaces of the wick structures 
via electrostatic interactions. As the liposomes contain the membrane-fusible lipid DOPE, 
membrane fusion among the liposomes occurs and the wick structures are covered with two 
lipid membranes. 
 
Figure 2.  
Polyacrylamide gel electrophoresis of siRNA after incubation with PLL at various N/P ratios 
Samples prepared by mixing siRNA with PLL at various N/P ratios were subjected to 
polyacrylamide gel electrophoresis. The gel was stained with SYBR Gold and observed under 
UV light. The lower band corresponds to free siRNA, while the higher band is attributed to wick 
structures comprised of siRNA with PLL.  
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Figure 3.  
Fluorescence intensity of EtBr intercalated in siRNA/PLL complexes prepared at various N/P 
ratios 
Fluorescence intensity of EtBr was measured after addition of the dye with a 
suspension of siRNA/PLL complexes prepared at various N/P ratios. EtBr fluoresces upon 
intercalation into double stranded siRNA structures. Low fluorescence intensity is indicative of 
a tightly bound siRNA/PLL complex.  
 
Figure 4.  
Sucrose density gradient fractionation of FNCs 
For sucrose density gradient fraction analysis, FNCs comprised of Alexa546-labeled 
siRNA and NBD-labeled lipid membranes were prepared. After sucrose density gradient 
fractionation of FNCs, fluorescence intensities of Alexa546-labeled siRNA (closed triangle) and 
NBD-labeled lipid (open square) in each fraction were measured at excitation 546 nm/emission 
573 nm and excitation 459 nm/emission 534 nm, respectively.   
 
Figure 5.  
RNase protection assay of wick structures and FNCs 
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Samples were treated with RNase (10 g/ml) for 2 h at 37°C, then subjected to 
agarose gel electrophoresis. After the electrophoresis, the gel was stained with SYBR Gold 
solution for 30 min, and observed under a UV transilluminator. 
 
Figure 6.  
TEM image of FNCs treated after negative staining  
FNCs stained with phosphor tungstic acid were observed by TEM. The bar represents 
100 nm.  
 
Figure 7. 
Effect of FNCs encapsulating anti-luciferase siRNA on luciferase activity 
FNCs encapsulating anti-luciferase siRNA or Lipofectamine 2000/anti-luciferase 
siRNA complexes were transfected into B16-F1 cells stably expressing luciferase. After a 48 h 
incubation at 37°C, the luciferase activity was measured. Data are means ± SD obtained from 3 
different samples. *p < 0.05, **p < 0.01. 
 
Figure 8. 
Confocal microscopy of the cancer spheroid after addition of various FNCs 
31 
 
 A suspension of FNCs encapsulating Alexa546-labeled siRNA was added to the 
spheroid. After 24 h incubation at 37°C, cell nuclei of the spheroid were stained with 
Hechest33342 for 10 min. The spheroid was then observed with a confocal laser scanning 
microscope. Confocal images in the x-y plane at 54-60 m distance (direction along the z-axis) 
from surface of 3D-cultured B16-F1 cells. Scale bars: 50 m. 
 
Figure 9 
Effect of various FNCs encapsulating anti-luciferase siRNA on luciferase activity 
Various FNCs encapsulating anti-luciferase siRNA were transfected into B16-F1 cells 
stably expressing luciferase. After a 48 h incubation at 37°C, the luciferase activity was 
measured. Suppression activity of the FNCs was obtained by dividing the decrease in luciferase 
activity by the luciferase activity of untreated cells. Data are means ± SD obtained from 3 
different samples.  
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Supplemental figure 1
Supplemental figure 1. TEM image of FNCs with a broader scope treated 
after negative staining 
FNCs stained with phosphor tungstic acid were observed by TEM. The bar 
represents 100 nm. 
Supplemental figure 2
Supplemental figure 2. Atomic force microscope (AFM) image of siRNA/PLL 
complexes prepared at N/P=0.8
The sample diluted up to 10 times was dropped on freshly cleaved mica, 
then the mica was dried for two hours in the desiccator.  After that, the 
sample was observed by tapping mode with AFM Nanoscope IIIa (Digital 
Instruments Inc. NY USA). 
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Supplemental figure 3. Atomic force microscope (AFM) image of FNC
The sample diluted up to 10 times was dropped on freshly cleaved mica, then 
the mica was dried for two hours in the desiccator.  After that, the sample was 
observed by tapping mode with AFM Nanoscope IIIa (Digital Instruments Inc. 
NY USA). 
Supplemental figure 3
Supplemental figure 4
0
25
50
75
100
Non treated Naked anti-
Luc siRNA
Naked anti-
GFP siRNA
Anti-GFP +
Lipofectamine
2000
Anti-GFP
FNC
R
e
la
ti
v
e
 lu
c
if
e
ra
s
e
 a
c
ti
v
it
y
 
v
s
 n
o
n
-t
re
a
tm
e
n
t
(%
)
Supplemental figure 4. Effect of FNCs encapsulating anti-GFP siRNA on 
luciferase activity
FNCs encapsulating anti-GFP siRNA or Lipofectamine 2000/anti-GFP siRNA 
complexes were transfected into B16-F1 cells stably expressing luciferase. 
After a 48 h incubation at 37°C, the luciferase activity was measured. Data 
are means ± SD obtained from 3 different samples. 
